Top Page
Mesoblast Limited
(Sydney:MSB)
Mesoblast Limited (MSB) vs. iShares MSCI Australia ETF (EWA)
Mesoblast Limited Business Overview & Revenue Model
Mesoblast Limited Earnings Call Summary
Mesoblast Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.67M | 17.20M | 5.90M | 7.50M | 10.21M | 7.46M |
| Gross Profit | -22.57M | 12.07M | -35.17M | -47.42M | -53.36M | -78.28M |
| EBITDA | -49.42M | -73.66M | -56.08M | -58.55M | -76.57M | -107.60M |
| Net Income | -103.35M | -102.14M | -87.96M | -81.89M | -91.35M | -98.81M |
Balance Sheet | ||||||
| Total Assets | 653.32M | 784.68M | 669.15M | 669.41M | 662.14M | 744.72M |
| Cash, Cash Equivalents and Short-Term Investments | 38.03M | 161.16M | 62.56M | 70.92M | 60.03M | 136.88M |
| Total Debt | 126.11M | 128.16M | 118.92M | 116.50M | 106.91M | 105.50M |
| Total Liabilities | 192.06M | 187.24M | 188.80M | 167.58M | 165.10M | 163.32M |
| Stockholders Equity | 461.26M | 597.44M | 480.36M | 501.84M | 497.04M | 581.40M |
Cash Flow | ||||||
| Free Cash Flow | -21.07M | -50.68M | -48.79M | -63.58M | -66.01M | -108.33M |
| Operating Cash Flow | -20.66M | -49.95M | -48.46M | -63.27M | -65.78M | -106.68M |
| Investing Cash Flow | 618.00K | 120.00K | -97.00K | -194.00K | -232.00K | -1.65M |
| Financing Cash Flow | 4.39M | 147.34M | 40.25M | 74.50M | -9.87M | 114.47M |
Mesoblast Limited Technical Analysis
Mesoblast Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $2.71B | 18.26 | 54.79% | ― | 12.35% | 26.73% | |
| ― | $581.83M | 16.04 | 15.90% | 0.44% | 7.76% | 1.55% | |
| ― | $3.30B | ― | -18.95% | ― | 198.58% | 3.97% | |
| ― | AU$44.16M | ― | -49.72% | ― | ― | 10.78% | |
| ― | AU$419.50M | ― | -35.86% | ― | ― | -19.21% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$339.93M | -34.96 | -89.70% | ― | 42.05% | -0.84% |
Mesoblast Limited Corporate Events
Mesoblast Limited has released its Annual Report for 2025, highlighting its commitment to corporate governance and ethical management. The report, approved by the Board of Directors, outlines the company’s governance framework, emphasizing its dedication to transparency and accountability, which is crucial for maintaining stakeholder trust and industry leadership.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, in Melbourne. The company encourages shareholders to attend in person or view the meeting online. Shareholders can vote in person or by proxy and are invited to submit questions in advance. This AGM is a crucial event for stakeholders to engage with the company’s management and discuss its performance and strategic direction.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This release is significant as it reinforces Mesoblast’s dedication to maintaining high governance standards, potentially impacting investor confidence and stakeholder trust.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited reported a significant 69% increase in net revenues for its product Ryoncil® in the second quarter following its launch, driven by increased physician adoption and reimbursement from commercial and government payers. The assignment of a permanent J-Code by the Centers for Medicare and Medicaid Services is expected to further enhance product adoption. The company has onboarded 40 transplant centers and expanded coverage to over 260 million US lives. Mesoblast is also planning a pivotal trial for Ryoncil® in adults with severe SR-aGvHD, potentially expanding its market reach. The company holds a strong cash position and is exploring additional funding options to support its operations and growth.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited, a company involved in the development of regenerative medicine products. The change in their substantial holding status is due to various transactions involving securities lending, purchasing, and sales, as well as the rehypothecation of client securities. This shift in holdings may impact Mesoblast’s market perception and investor confidence, as JPMorgan’s involvement was significant in terms of voting securities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited announced the cessation of certain securities, with 120,000 options lapsing due to unmet conditions and over 2 million options expiring without exercise. This development may impact the company’s financial strategy and investor relations, as it reflects on the company’s ability to meet certain operational milestones.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited announced the application for the quotation of 3,000,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities are issued under an employee incentive scheme and are not subject to transfer restrictions. This move is part of Mesoblast’s strategy to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement positively.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited reported a significant 66% increase in revenue for its product Ryoncil, reaching US$21.9 million in the second quarter post-launch. This growth is attributed to the adoption of Ryoncil for treating pediatric steroid-refractory acute graft-versus-host disease, supported by reimbursement from commercial and government payers. The recent assignment of a permanent J-Code by the Centers for Medicare and Medicaid Services is expected to further enhance product adoption. This development strengthens Mesoblast’s position in the cellular medicine industry and indicates positive implications for stakeholders, highlighting the company’s potential for continued growth and market expansion.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited announced that its product Ryoncil® has received a permanent J-Code from the United States Medicare & Medicaid Services, facilitating easier billing and reimbursement. This milestone is expected to enhance patient access to Ryoncil®, particularly for children with life-threatening steroid-refractory acute graft-versus-host disease, and improve the product’s commercialization prospects.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited announced that its allogeneic cell therapy products, manufactured in the U.S. from U.S. donors, are designated as U.S. origin products and are not subject to tariffs on imported branded or patented pharmaceutical products. This designation, particularly for Ryoncil®, the only FDA-approved allogeneic mesenchymal stromal cell therapy, reinforces Mesoblast’s strategic positioning in the market by ensuring cost stability and regulatory compliance, potentially benefiting stakeholders by maintaining competitive pricing and access in the U.S. market.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that State Street Corporation and its subsidiaries have ceased to be substantial holders in the company as of September 18, 2025. This change in substantial holding could impact Mesoblast’s shareholder composition and influence voting dynamics, potentially affecting the company’s strategic decisions and market positioning.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that State Street Corporation and its subsidiaries have ceased to be substantial holders of the company’s voting securities as of September 11, 2025. This change in substantial holding may impact Mesoblast’s shareholder structure and could influence the company’s strategic decisions and market perception.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited announced the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell product, at global healthcare conferences. The company reported strong initial sales for treating pediatric SR-aGvHD and plans to expand Ryoncil® into adult SR-aGvHD and inflammatory bowel disease, alongside advancing its second-generation product Rexlemestrocel-L. This launch and expansion strategy is expected to enhance Mesoblast’s market positioning and operational growth in the cellular medicine industry.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced a change in the director’s interest, specifically pertaining to Gregory George. The company disclosed that George, through G to the Fourth Investments, LLC, acquired 9,640,072 shares and 325,901 American Depositary Shares (ADS), each representing 10 ordinary shares, in an on-market purchase. This acquisition reflects a significant investment amounting to approximately US$18.8 million, indicating a potential strategic move to strengthen his stake in the company.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced a proposed issue of 5,000,000 warrants as part of a new securities placement. This move is expected to enhance the company’s financial flexibility and support its ongoing projects in the biotechnology sector, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited announced it has entered into convertible note subscription agreements with SurgCenter principals and existing shareholders to issue up to US$50 million in unsecured convertible notes. This funding, subject to shareholder approval, will be used to repay or reduce existing loan amounts and support general working capital. The move is part of Mesoblast’s strategy to optimize its capital structure and support pipeline growth opportunities. The convertible notes have a maturity date of five years, with an option for investors to convert them into ordinary shares or ADRs at a premium price. This financial maneuver is expected to enhance Mesoblast’s operational flexibility and strengthen its market positioning in the cellular medicine industry.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited is an Australian biotechnology company specializing in allogeneic cellular medicines for inflammatory diseases, with a focus on developing treatments based on its mesenchymal lineage cell platform.
Mesoblast Limited announced a significant milestone with the FDA approval and successful commercial launch of Ryoncil®, the first mesenchymal stromal cell product approved in the US for treating SR-aGvHD in children. The company reported a substantial increase in revenue driven by Ryoncil®’s launch, with plans to expand its indications and explore new markets. Mesoblast’s strategic initiatives, including strengthening its board and expanding insurance coverage for Ryoncil®, position it for growth in the biotechnology sector.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$2.97 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced a webcast to discuss its operational highlights and financial results for the fiscal year ending June 30, 2025. The company continues to focus on expanding its cell therapy offerings, with ongoing developments in treatments for inflammatory diseases, heart failure, and chronic low back pain. Mesoblast’s strong intellectual property portfolio and proprietary manufacturing processes position it well for future growth and global market expansion.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$2.97 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that State Street Global Advisors Limited, a subsidiary of State Street Corporation, has ceased to be a substantial holder in the company as of August 21, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market dynamics, as State Street’s involvement in voting securities has been altered.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$2.97 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.